Method and system for treating hepatitis C

• US 20060189559A1
• Filed: 12/16/2005
• Published: 08/24/2006
• Est. Priority Date: 12/20/2004
• Status: Abandoned Application

• Current Assignee: Codman & Shurtleff Incorporated (Johnson & Johnson)
• Original Assignee: Codman & Shurtleff Incorporated (Johnson & Johnson)
• Inventors: Zhao, Ruilin, Baert, Lieven, Simmen, Kenneth Alan
• Application Number:
  US11/305,707
• Publication Number:
  US 20060189559A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: A61M 2210/1071 Liver; Hepar
• CPC Class Codes: A61M 5/14232 Roller pumps
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61M 5/152 pressurised by contraction of elastic reservoirs containers for dispensing contents by contraction of an elastic bag provided therein, in general B65D83/0061

Abstract

A method and system for treating Hepatitis C includes using an implantable pump and an outlet catheter. A proximal end of the outlet catheter is fluidly connected to an outlet port of the pump. A distal end of the outlet catheter is sized to deliver medication from the pump to a liver of living organism, preferably a human being. By delivering medication directly to the liver the effects of the antiviral therapeutics are enhanced, and the impact of Hepatitis C infection is reduced.

Claims

1. A method of treating a patient infected with Hepatitis C, said method comprising the steps of:

filling an implantable drug infusion pump with an at least one HCV inhibitor

locally delivering an HCV inhibitory effective amount of at least one HCV inhibitor directly to the liver by way of an implantable drug infusion pump having an outlet catheter delivering the at least one HCV inhibitor directly to the desired location in the liver or to any body vessel outside the liver that drains body fluid into the liver.

2. The method of claim 1, wherein the catheter delivers the at least one HCV inhibitor directly to the portal vein.

3. The method of claim 1, wherein the at least one HCV inhibitor includes small interfering RNA (Si RNA).

4. The method of claim 1, wherein the infusion pump is a bellows reservoir pump.

5. The method of claim 1, wherein the infusion pump is a peristaltic pump.

6. A method for treating Hepatitis C by use of an implantable pump and an outlet catheter having a proximal end and a distal end, said method comprising the steps of:

surgically implanting the implantable pump in a body of a patient;

fluidly connecting the proximal end of the outlet catheter to the pump;

fluidly connecting the distal end of the outlet catheter to the desired location in the patient'"'"'s liver or to any body vessel outside the patient'"'"'s liver, draining body fluid into the liver

operating the pump to deliver medication by way of the outlet catheter to the liver; and

whereby the effects of Hepatitis C are reduced.

7. The method of claim 6, wherein the catheter delivers the at least one HCV inhibitor directly to the portal vein.

8. The method of claim 6, wherein the at least one HCV inhibitor is a nucleic acid based therapeutic.

9. The method of claim 6, wherein the at least one HCV inhibitor includes small interfering RNA (Si RNA).

10. The method of claim 6, wherein the infusion pump is a bellows reservoir pump.

11. The method of claim 6, wherein the infusion pump is a peristaltic pump.

12. A system for treating Hepatitis C comprising:

an implantable pump having an outlet port;

an outlet catheter having a proximal end and a distal end, said proximal end being fluidly connected to said outlet port, said distal end of said outlet catheter being sized to deliver medication from said pump to a liver of living organism.

13. The system according to claim 12, wherein said living organism is a human being.

14. The system of claim 12, wherein the infusion pump is a bellows reservoir pump.

15. The method of claim 12, wherein the infusion pump is a peristaltic pump.